Improved effector activity and memory CD8 T cell development by IL-2 expression during experimental respiratory syncytial virus infection.
Respiratory syncytial virus (RSV) is a major cause of lower respiratory infection in young children and the elderly. Studies of mice suggest that RSV suppresses the effector activity of CD8 T cells and the development of pulmonary CD8 T cell memory, in which the impaired effector activity could be recovered by in vitro IL-2 treatment. To investigate the effect of in vivo IL-2 expression on RSV immunity, mice were infected with RSV followed by administration of replication-defective adenovirus expressing IL-2. The effector activity of RSV M2-specific CD8 T cells and the development of CD8 T cell memory in the lung was significantly increased by IL-2 expression. Furthermore, the Ab responses against RSV were augmented by IL-2. Interestingly, weight loss and illness caused by RSV challenge were substantially reduced by IL-2 priming, suggesting that the pathogenesis of RSV-related disease could be prevented by IL-2-mediated enhancement of beneficial immune responses. Thus, our results show that IL-2 has potential to be used as a vaccine adjuvant against RSV infection.
Chang
Jun
J
Department of Life Science, Pohang University of Science and Technology, Pohang 790-784, Republic of Korea. jeje@postech.ac.kr
Choi
So Young
SY
Jin
Hyun Tak
HT
Sung
Young Chul
YC
Braciale
Thomas J
TJ
D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000096:biosynthesis* / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology* / Q000276:immunology* / Q000473:pathology; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D002465:Cell Movement / Q000235:genetics / Q000276:immunology; D002478:Cells, Cultured; D005260:Female; D005822:Genetic Vectors; D007156:Immunologic Memory / Q000235:genetics; D007376:Interleukin-2 / Q000008:administration & dosage / Q000096:biosynthesis* / Q000494:pharmacology / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D011024:Pneumonia, Viral / Q000276:immunology / Q000473:pathology / Q000628:therapy; D011995:Recombination, Genetic; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D014779:Virus Replication / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007376:Interleukin-2